Referencias bibliográficas 1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology. febrero de 2014;70(2):338-51. 2. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Annals of Nutrition and Metabolism. 2015;66(1):8-16. 3. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657. 4. Holm E, Esmann S, Jemec G. The handicap caused by atopic dermatitis - sick leave and job avoidance. Journal of the European Academy of Dermatology and Venereology. marzo de 2006;20(3):255-9. 5. Gittler JK et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol.2012; 130(6):1344-1354. 3. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology. febrero de 2014;70(2):338-51. 6. www.NationalEczema.org/AtopicDermatitis/What is Atopic Dermatitis/P1/lines1-2. [Internet]. Disponible en: https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/ Revisado: Septiembre 2019. 7. A. Torrelo. Atopic dermatitis in different skin types. What is to know?. JEADV 2014, 28 (Suppl. 3), 2–4. 8. https://www.niams.nih.gov/health-topics/atopic-dermatitis - «What is it?», Para 1 & 2 [Internet]. Disponible en: https://www.niams.nih.gov/health-topics/atopic-dermatitis. Revisado: Septiembre 2019. 9. Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. Journal of Allergy and Clinical Immunology. julio de 2006;118(1):226-32. 10. Yosipovitch G, Papoiu ADP. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. julio de 2008;8(4):306-11. 11. Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Experimental Dermatology. febrero de 2002;11(1):12-24. 12. Bieber T. Atopic Dermatitis. Annals of Dermatology. 2010;22(2):125. 13. Myers, Jane, E. The wheel of wellness counselinf for wellness: A holistic model for treatment planning. Journal of counseling and development. 2000. 14. Rosenkranz MA, Davidson RJ, MacCoon DG, Sheridan JF, Kalin NH, Lutz A. A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. Brain, Behavior, and Immunity. enero de 2013;27:174-84. 15. Neff KD, Kirkpatrick KL, Rude SS. Self-compassion and adaptive psychological functioning. Journal of Research in Personality. febrero de 2007;41(1):139-54. 16. Berkman LF, Glass T, Brissette I, Seeman TE. From social integration to health: Durkheim in the new millennium p. Social Science. 2000;15. 17. Mayo Clinic.org. Support groups, 2015/P1/Para1/lines4-5; Para2/lines1-5. [Internet]. Disponible en: https://www.mayoclinic.org/healthy-lifestyle/stress-management/in-depth/support-groups/art-20044655. 18. Lifschitz C. The Impact of Atopic Dermatitis on Quality of Life. Annals of Nutrition and Metabolism. 2015;66(1):34-40. 19. Suárez-Fariñas M, et al. Non lesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954-964. © Elsevier Editeur. Todos los derechos reservados. 20. Rerknimitr, P., Otsuka, A., Nakashima, C. et al. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regener 37, 14 (2017). https://doi.org/10.1186/s41232-017-0044-7. 21. A.J. Hendricks et al. Sweat mechanisms and dysfunctions in atopic dermatitis. Journal of Dermatological Science 89 (2018) 105–11122. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017:5;691-706.23. Parikh P. OPEN-ing up about asthma. Allergy & Asthma Today. 2016;14:22-23. Disponible en http://mydigimag.rrd.com/publication/?i=326085#{“issue_id”:326085,”page”:20}. Último acceso en noviembre de 2018 24. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009 25. Rabe, K. F., Vermeire, P. A., Soriano, J.B., Maier, W.C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J. 2000;16:802-807.26. Fletcher M, Hiles D. Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma from the UK. Prim Care Resp J. 2013;22(4):431-43827. Murphy KR, et al. Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc. 2012 Jan-Feb;33(1):54-6428. Andrews KL et al. Stigma: Still an Important Issue for Adults With Asthma. Journal of Asthma and Allergy Educators. Vol 4, Issue 4, 201329. Reddel HK, et al. Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. BMJ Open. 2017;7:e016688. Disponible en: https://bmjopen.bmj.com/content/7/9/e016688.full?ijkey=JWTMTG1oSaXXktC&keytype=ref 30. Bülow AV, et al. The Prevalence of Severe Asthma and Low Asthma Control Among Danish Adults. J Allergy Clin Immunol. 2014;2(6):759-767 31. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2018. Disponible en: http://ginasthma.org/download/832/. Último acceso: abril de 2018 32. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009 33. Global Initiative for Asthma (GINA). Pocket Guide for Asthma Management and Prevention. 2018. Disponible en: https://ginasthma.org/2018-pocket-guide-for-asthma-management-and-prevention/. Último acceso en octubre de 2018 34. Juniper EF, GH Guyatt, PJ Ferrie, et al. Measuring Quality of Life in Asthma. Am Rev Respir Dis. 1993;147:832-8. 35. Asthma and Allergy Foundation of America. My Life with Asthma Survey Overview. Disponible en: http://www.aafa.org/media/1684/my-life-with-asthma-in-2017-survey-findings-report.pdf. Último acceso en octubre de 2018 36. Rand C, et al. Mediators of asthma outcomes. J Allergy Clin Immunol. 2012:129(3);136-141 37. Asthma and Allergy Foundation of America. My Life with Asthma Report. Disponible en http://www.aafa.org/my-life-with-asthma-report/. Último acceso en octubre de 2018 38. The European Academy of Allergy and Clinical Immunology (EAACI). Advocacy Manifesto: Tackling the Allergy Crisis in Europe - Concerted Policy Action Needed. Disponible en: http://www.eaaci.org/documents/EAACI_Advocacy_Manifesto.pdf. Último acceso en octubre de 2018 39. Behmanesh F, et al. Evaluation of anxiety and depression in mothers of children with asthma. Electron Physician. 2017:9(12);6058-6062 40. European Respiratory Society. European Lung White Book, Chapter 2: The economic burden of lung disease. Disponible en: http://www.erswhitebook.org/files/public/Chapters/02_economics.pdf. Último acceso en octubre de 2018 41. Daugherty J, et al. The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis. J Asthma. 2017 Sep;19:1-8 42. Nunes C, Pereira AM, Morais-Ameida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1 43. Chipps et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012 Aug;130(2):332-42. 44. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50 45. Woodruff PG, et al. T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009;180(5):388–395 46. Peters MC, Mekonnen ZK, Yuan S, et al. Measure of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388-394 47. Fahy et al. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2015 Jan;15(1):57-65. 48. Dunican EM, Fahy JV. The Role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc.2015;12 Suppl 2:S144–S149 49. Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347-58 50. Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308(2):L130-40 51. Matsusaka M, K Fukunaga, H Kabata, et al. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract 2018;6(1):274-276.e2 52. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017. 47(2): 161-175. 53. Partridge, M. R. Delivering optimal care to the person with asthma: what are the key components and what do we mean by patient education? Eur Respir J. 1995: 8: 298-305. 54. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffi eld, European Respiratory Society, 2017. 55. Global Initiative for Asthma. Difficult-to-treat & severe asthma in adolescent and adult patients, 2019 (Iniciativa Global para el Asma. Asma grave y difícil de tratar en pacientes adolescentes y adultos, 2019). https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf Último acceso: 13 de marzo de 2020. 56. Chung, K. F., et al (2013). International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 43(2), 343-373. https://doi.org/10.1183/09031936.00202013 57. The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network, 2018 58. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials [published correction appears in Lancet. 2019 Nov 2;394(10209):1618 59. Guilemany, J. M. (2006). ¿Cómo diagnosticar a un paciente con rinosinusitis crónica/poliposis nasal? Jano: Medicina y humanidades, 1665, 29-34. https://dialnet.unirioja.es/servlet/articulo?codigo=2376595 60. Bachert C, Gevaert E. Advances in rhinitis and rhinosinusitis in 2015. J Allergy Clin Immunol. 2016;138(5):1277-1283 61. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50 62. Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42 63. Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27(6):473-478 64. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280-1289 65. Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28(3):192-198 66. Yasir M, Goyal A, Bansal P, et al. Corticosteroid Adverse Effects. [Updated 2020 Apr 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK531462/ 67. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-555 68. Bassiouni A, Wormald PJ. Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope. 2013;123(1):36-41 69. Wynn R, Har-El G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811-813 70. Bebés y niños con dematitis atópica. (2016, noviembre 4). MedPlus; MedPlus Medicina Prepagada. https://www.medplus.com.co/bebes-y-ninos-con-dematitis-atopica/ (Consultado el 09/06/2023) 71. Sanofi Genzyme pone de manifiesto la falta de información con relación a las enfermedades inflamatorias tipo 2 - Sanofi en España. (s/f). Sanofi.es. Recuperado el 7 de septiembre de 2023, de https://www.sanofi.es/es/noticias/enfermedades-inflamatorias-tipo2-type2-inflamation-connection